Download pdf
Discovery and validation of putative anticancer genes in lung adenocarcinoma
- 1 The Loomis Chaffee School
* Author to whom correspondence should be addressed.
Abstract
Lung adenocarcinoma (LUAD) is a significant subtype of lung cancer, and understanding the roles of tumor suppressor genes in LUAD remains crucial. In this study, we aimed to identify and experimentally validate potential tumor suppressor genes selected from online databases. By analyzing the TCGA cancer database, we identified genes exhibiting significant differential expression between normal and tumor tissues in LUAD, particularly focusing on genes with lower expression levels in tumors associated with shortened survival periods. Subsequently, we selected UNC5B, DAB2IP, SEMA3F, PPM1L, and AXIN2 as candidate genes and performed knockdown experiments using LUAD cell line HCC827. Our findings revealed that all selected genes, except UNC5B, conferred tumor-like properties when knocked out, suggesting their potential as anti-tumor agents. These results contribute to the understanding of LUAD pathogenesis and highlight the significance of studying tumor suppressor genes in the context of cancer development and patient survival.
Keywords
Lung adenocarcinoma, Tumorigenesis, Knock out, Gene expression
[1]. D. Hanahan and R. A. Weinberg, “Hallmarks of cancer: the next generation,” cell, vol. 144, no. 5, pp. 646-674, 2011.
[2]. L. A. Loeb, “Mutator phenotype may be required for multistage carcinogenesis,” Cancer research, vol. 51, no. 12, pp. 3075-3079, 1991.
[3]. J. Zugazagoitia, C. Guedes, S. Ponce, I. Ferrer, S. Molina-Pinelo, and L. Paz-Ares, “Current challenges in cancer treatment,” Clinical therapeutics, vol. 38, no. 7, pp. 1551-1566, 2016.
[4]. R. S. Herbst, D. Morgensztern, and C. Boshoff, “The biology and management of non-small cell lung cancer,” Nature, vol. 553, no. 7689, pp. 446-454, 2018.
[5]. R. Chalela, V. Curull, C. Enriquez, L. Pijuan, B. Bellosillo, and J. Gea, “Lung adenocarcinoma: from molecular basis to genome-guided therapy and immunotherapy,” Journal of thoracic disease, vol. 9, no. 7, p. 2142, 2017.
[6]. T. Hart et al., “High-resolution CRISPR screens reveal fitness genes and genotype-specific cancer liabilities,” Cell, vol. 163, no. 6, pp. 1515-1526, 2015.
[7]. T. Wang et al., “Gene essentiality profiling reveals gene networks and synthetic lethal interactions with oncogenic Ras,” Cell, vol. 168, no. 5, pp. 890-903. e15, 2017.
[8]. C. Kandoth et al., “Mutational landscape and significance across 12 major cancer types,” Nature, vol. 502, no. 7471, pp. 333-339, 2013.
[9]. N. B. Charbe et al., “Small interfering RNA for cancer treatment: overcoming hurdles in delivery,” Acta Pharmaceutica Sinica B, vol. 10, no. 11, pp. 2075-2109, 2020.
[10]. S. Wu et al., “High expression of UNC5B enhances tumor proliferation, increases metastasis, and worsens prognosis in breast cancer,” Aging (Albany NY), vol. 12, no. 17, p. 17079, 2020.
[11]. S. Okazaki et al., “Clinical significance of UNC5B expression in colorectal cancer,” International journal of oncology, vol. 40, no. 1, pp. 209-216, 2012.
Cite this article
Zhang,D. (2024). Discovery and validation of putative anticancer genes in lung adenocarcinoma. Theoretical and Natural Science,32,155-163.
Data availability
The datasets used and/or analyzed during the current study will be available from the authors upon reasonable request.
Disclaimer/Publisher's Note
The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of EWA Publishing and/or the editor(s). EWA Publishing and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.
About volume
Volume title: Proceedings of the 2nd International Conference on Modern Medicine and Global Health
© 2024 by the author(s). Licensee EWA Publishing, Oxford, UK. This article is an open access article distributed under the terms and
conditions of the Creative Commons Attribution (CC BY) license. Authors who
publish this series agree to the following terms:
1. Authors retain copyright and grant the series right of first publication with the work simultaneously licensed under a Creative Commons
Attribution License that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this
series.
2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the series's published
version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial
publication in this series.
3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and
during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See
Open access policy for details).